Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel Free CRON Stock Alerts

Cronos Group (CRON) Competitors

Cronos Group logo
C$4.57 +0.03 (+0.66%)
As of 11:46 AM Eastern
Compare

CRON vs. APHA, BHC, MJN, CARA, and GUD

Should you buy Cronos Group stock or one of its competitors? Cronos Group's main competitors and comparable companies include Aphria (APHA), Bausch Health Companies (BHC), Cronos Group (MJN), Cara Operations (CARA), and Knight Therapeutics (GUD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cronos Group compare to Aphria?

Cronos Group (TSE:CRON) and Aphria (TSE:APHA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Aphria'saverage media sentiment score.

Company Overall Sentiment
Cronos Group Neutral
Aphria Neutral

Cronos Group currently has a consensus price target of C$4.92, suggesting a potential upside of 8.30%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Aphria.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aphria
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

4.4% of Cronos Group shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cronos Group has higher earnings, but lower revenue than Aphria. Aphria is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$179.09M9.34-C$32.78MC$0.1923.89
AphriaC$611.06M0.00-C$637.39M-C$2.01N/A

Cronos Group has a net margin of 38.95% compared to Aphria's net margin of 0.00%. Cronos Group's return on equity of 6.46% beat Aphria's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group38.95% 6.46% -3.73%
Aphria N/A N/A N/A

Summary

Cronos Group beats Aphria on 10 of the 12 factors compared between the two stocks.

How does Cronos Group compare to Bausch Health Companies?

Cronos Group (TSE:CRON) and Bausch Health Companies (TSE:BHC) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Cronos Group has a net margin of 38.95% compared to Bausch Health Companies' net margin of -12.02%. Bausch Health Companies' return on equity of 87.57% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group38.95% 6.46% -3.73%
Bausch Health Companies -12.02%87.57%4.16%

Cronos Group presently has a consensus price target of C$4.92, suggesting a potential upside of 8.30%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts plainly believe Cronos Group is more favorable than Bausch Health Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Bausch Health Companies
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Cronos Group has higher earnings, but lower revenue than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$179.09M9.34-C$32.78MC$0.1923.89
Bausch Health CompaniesC$10.85B0.29-C$125.65M-C$2.94N/A

In the previous week, Bausch Health Companies had 2 more articles in the media than Cronos Group. MarketBeat recorded 2 mentions for Bausch Health Companies and 0 mentions for Cronos Group. Bausch Health Companies' average media sentiment score of 1.22 beat Cronos Group's score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the news media.

Company Overall Sentiment
Cronos Group Neutral
Bausch Health Companies Positive

Cronos Group has a beta of 1.288385, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Bausch Health Companies has a beta of 0.822142, suggesting that its share price is 18% less volatile than the broader market.

4.4% of Cronos Group shares are owned by institutional investors. Comparatively, 9.5% of Bausch Health Companies shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by company insiders. Comparatively, 11.3% of Bausch Health Companies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cronos Group beats Bausch Health Companies on 10 of the 16 factors compared between the two stocks.

How does Cronos Group compare to Cronos Group?

Cronos Group (TSE:CRON) and Cronos Group (CVE:MJN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

4.4% of Cronos Group shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cronos Group has a net margin of 38.95% compared to Cronos Group's net margin of 0.00%. Cronos Group's return on equity of 6.46% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group38.95% 6.46% -3.73%
Cronos Group N/A N/A N/A

Cronos Group has lower revenue, but higher earnings than Cronos Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$179.09M9.34-C$32.78MC$0.1923.89
Cronos GroupN/AN/AN/AN/AN/A

Cronos Group presently has a consensus price target of C$4.92, suggesting a potential upside of 8.30%. Given Cronos Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Cronos Group is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Cronos Group's average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company Overall Sentiment
Cronos Group Neutral
Cronos Group Neutral

Summary

Cronos Group beats Cronos Group on 8 of the 9 factors compared between the two stocks.

How does Cronos Group compare to Cara Operations?

Cara Operations (TSE:CARA) and Cronos Group (TSE:CRON) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

4.4% of Cronos Group shares are held by institutional investors. 46.4% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cronos Group has a net margin of 38.95% compared to Cara Operations' net margin of 0.00%. Cronos Group's return on equity of 6.46% beat Cara Operations' return on equity.

Company Net Margins Return on Equity Return on Assets
Cara OperationsN/A N/A N/A
Cronos Group 38.95%6.46%-3.73%

In the previous week, Cara Operations' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company Overall Sentiment
Cara Operations Neutral
Cronos Group Neutral

Cronos Group has a consensus target price of C$4.92, indicating a potential upside of 8.30%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts clearly believe Cronos Group is more favorable than Cara Operations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Operations
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Cara Operations has higher earnings, but lower revenue than Cronos Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara OperationsN/AN/AN/AN/AN/A
Cronos GroupC$179.09M9.34-C$32.78MC$0.1923.89

Summary

Cronos Group beats Cara Operations on 8 of the 9 factors compared between the two stocks.

How does Cronos Group compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Cronos Group (TSE:CRON) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Knight Therapeutics has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$547.31M1.92-C$30.73MC$0.1571.20
Cronos GroupC$179.09M9.34-C$32.78MC$0.1923.89

Cronos Group has a net margin of 38.95% compared to Knight Therapeutics' net margin of 2.72%. Cronos Group's return on equity of 6.46% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics2.72% 1.91% 0.51%
Cronos Group 38.95%6.46%-3.73%

In the previous week, Knight Therapeutics had 1 more articles in the media than Cronos Group. MarketBeat recorded 1 mentions for Knight Therapeutics and 0 mentions for Cronos Group. Knight Therapeutics' average media sentiment score of 0.32 beat Cronos Group's score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Knight Therapeutics Neutral
Cronos Group Neutral

Knight Therapeutics has a beta of -0.449151, suggesting that its share price is 145% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.288385, suggesting that its share price is 29% more volatile than the broader market.

Knight Therapeutics presently has a consensus target price of C$9.50, suggesting a potential downside of 11.05%. Cronos Group has a consensus target price of C$4.92, suggesting a potential upside of 8.30%. Given Cronos Group's higher probable upside, analysts clearly believe Cronos Group is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

22.8% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.4% of Cronos Group shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Comparatively, 46.4% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cronos Group beats Knight Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Cronos Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRON vs. The Competition

Export
MetricCronos GroupPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$1.68BC$12.43BC$7.28BC$12.63B
Dividend YieldN/A2.63%2.51%6.34%
P/E Ratio24.05807.81275.4437.52
Price / Sales9.40748.21559.808.41
Price / Cash1.6786.6577.1682.29
Price / Book1.539.1910.664.36
Net Income-C$32.78MC$2.84BC$3.50BC$299.09M
7 Day Performance-1.08%-3.85%-3.65%-0.27%
1 Month Performance1.11%-7.95%-8.06%-2.32%
1 Year Performance28.37%-5.71%2.58%14.22%

Cronos Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRON
Cronos Group
1.7158 of 5 stars		C$4.57
+0.7%		C$4.92
+7.6%		+29.0%C$1.68BC$179.09M24.05610
APHA
Aphria
N/AN/AN/AN/AC$5.24BC$611.06MN/A1,200
BHC
Bausch Health Companies
0.6811 of 5 stars		C$8.60
-2.2%		N/A-1.8%C$3.29BC$10.85BN/A20,300
MJN
Cronos Group
N/AC$12.15
-1.9%		N/A+0.0%C$1.73BN/AN/A7,600
CARA
Cara Operations
N/AN/AN/AN/AC$1.62BN/AN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:CRON) was last updated on 10/14/2026 by MarketBeat.com Staff.
From Our Partners
The AI Infrastructure Play Kevin O'Leary Is Backing
Kevin O'Leary became a strategic investor in a NASDAQ-listed AI infrastructure company, calling it essentially...
The Tomorrow Investor | Sponsoredtc pixel
Wall Street legend reveals his top AI stock before Oct. 20
Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...
Chaikin Analytics | Sponsoredtc pixel
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...
Monument Traders Alliance | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
How one AI fund pays investors every Thursday
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
Federal Reserve Reveals Disturbing New Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...
Weiss Ratings | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel